O23 Characterisation of populations with hepatitis C to improve access to antiviral therapy programs: a population-based linkage study

• M. Alavi,
• J. Amin,
• J. Grebely,
• M.G. Law,
• N.Z. Janjua,
• M. Krajden,
• B. Hajarizadeh,
• J. George,
• G.V. Matthews,
• S. Larney,
• L. Degenhardt,
• G.J. Dore

Affiliations

M. Alavi

Kirby Institute, University of New South Wales, Sydney, NSW, Australia

J. Amin

Kirby Institute, University of New South Wales, Sydney, NSW, Australia

J. Grebely

Kirby Institute, University of New South Wales, Sydney, NSW, Australia

M.G. Law

Kirby Institute, University of New South Wales, Sydney, NSW, Australia

N.Z. Janjua

British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada; School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada

M. Krajden

British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada

B. Hajarizadeh

Kirby Institute, University of New South Wales, Sydney, NSW, Australia

J. George

Storr Liver Centre, Westmead Millennium Institute, University of Sydney and Westmead Hospital, Westmead, NSW, Australia

G.V. Matthews

Kirby Institute, University of New South Wales, Sydney, NSW, Australia

S. Larney

National Drug and Alcohol Research Centre, Universit of New South Wales, Sydney, NSW, Australia

L. Degenhardt

National Drug and Alcohol Research Centre, Universit of New South Wales, Sydney, NSW, Australia

G.J. Dore

Kirby Institute, University of New South Wales, Sydney, NSW, Australia